Journal ArticleOPEN ACCESS

S196: ELRANATAMAB, A B-CELL MATURATION ANTIGEN (BCMA)-CD3 BISPECIFIC ANTIBODY, FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: EXTENDED FOLLOW UP AND BIWEEKLY ADMINISTRATION FROM MAGNETISMM-3

  • Mohty M
  • Tomasson M
  • Arnulf B
  • et al.
HemaSphere (2023) 7(S3) e1309654
DOI: 10.1097/01.hs9.0000967696.13096.54
N/ACitations
Citations of this article
4Readers
Mendeley users who have this article in their library.

This article is free to access.

Cite

CITATION STYLE

APA

Mohty, M., Tomasson, M. H., Arnulf, B., Bahlis, N. J., Rodríguez-Otero, P., Martinez-Lopez, J., … Lesokhin, A. (2023). S196: ELRANATAMAB, A B-CELL MATURATION ANTIGEN (BCMA)-CD3 BISPECIFIC ANTIBODY, FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: EXTENDED FOLLOW UP AND BIWEEKLY ADMINISTRATION FROM MAGNETISMM-3. HemaSphere, 7(S3), e1309654. https://doi.org/10.1097/01.hs9.0000967696.13096.54

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free